Verici Dx has raised $11.2M in new funding. The company develops prognostic tests designed to show how a patient will respond, and is responding, to an organ transplant.
The round adds capital to a business built around a narrow but consequential problem in transplant care: predicting outcomes rather than reacting to them after the fact. Verici Dx trades under the ticker VRCI. Details on the round's type and its investors were not disclosed.














